Galen, the AI-powered cancer diagnostic platform developed by Ibex Medical Analytics, is set to roll out across Europe, following a deal between Ibex and diagnostic services provider Unilabs. Utilising algorithms and machine learning, Galen analyses tissue biopsy images in order to generate insights which pathologists can use to make a diagnosis.
The platform is designed to help produce faster, more accurate diagnoses which can improve patient outcomes. The insights Galen produces include cancer heatmaps, case prioritisation and tumour grading and measurement, among others. These are designed to aid pathologists in making assessments which are then vital in enabling oncologists to make correct decisions regarding treatment.
The European roll-out will commence in Sweden, before continuing throughout the 16 countries in which Unilabs operates. Unilabs Chief Medical & Operations Officer Dr. Christian Rebhan said: “This cutting-edge AI technology will help our teams quickly prioritise urgent cases, speed up diagnosis, and improve quality by adding an extra set of digital eyes.”
“When it comes to cancer, the earlier you catch it, the better the prognosis – so getting us critical results faster will help save lives. The partnership with Ibex underlines Unilabs’ pioneering role in digital pathology and represents yet another step in our ambition to become the most digitally enabled provider of diagnostic services in Europe.”
Ibex CEO and co-founder Joseph Mossel added: “Ibex is transforming cancer with innovative AI solutions across the diagnostic pathway. We are excited to partner with Unilabs to deploy our AI solutions and empower their pathologists with faster turnaround times and quality diagnosis.”
“This cooperation follows a thorough evaluation of our technology at Unilabs, and demonstrates the robustness and utility of our platform for everyday clinical practice."